Objective: Ovarian cancer screening (OCS) for BRCA1/2 mutation carriers was stopped in our family cancer clinic in 2009 because of its ineffectiveness. The study objective was to investigate the effect of stopping OCS on the timing and uptake of risk-reducing salpingo-oophorectomy (RRSO) and on the percentage of occult cancers in the specimens.
Methods: 419 BRCA1/2 mutation carriers were recruited between January 1999 and June 2013. Uptake, timing and the outcome of the RRSO specimens before stopping OCS (period I) were compared to those after stopping OCS (period II).
Results: The percentage of women undergoing RRSO within the recommended age range increased from 81% to 95%. Receiving DNA test results in period II independently predicted a shorter time interval to RRSO (hazard ratio: 2.48, 95% confidence interval: 1.81-3.39). The incidence of detecting occult cancers in RRSO specimens before and after stopping OCS was 1.3% and 1.8%, respectively, and was not statistically significantly different.
Conclusions: The presentation of risk management options to women may influence their decision. The increased patient awareness of the ineffectiveness of OCS could have led to a higher percentage of women undergoing RRSO and doing so more often within the recommended age range.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.maturitas.2014.12.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT).
Ther Adv Respir Dis
January 2025
Department of Chest Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shipai Road, Beitou District, Taipei City 11217, Taiwan.
Background: REMIT is the first real-world study of mepolizumab effectiveness in patients with severe asthma (SA) in Taiwan.
Objectives: The primary objective evaluated changes in clinically significant exacerbations (CSEs; defined as use of oral corticosteroids (OCS) or emergency department (ED) visits and/or hospitalizations) in the 12 months pre- and post-mepolizumab treatment. Secondary objectives assessed changes in the number of CSEs requiring ED visits/hospitalizations and daily maintenance OCS (mOCS) dosage 12 months pre- and post-mepolizumab treatment.
Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS).
Pneumologie
August 2023
Klinik für Pneumologie, Medizinische Hochschule Hannover, Hannover.
Background: The introduction of monoclonal antibodies (biologics) has revolutionized the therapy of severe asthma. Even though there is a response in the majority of patients, the degree of response varies. To date criteria for assessment of response to biologics are not consistently defined.
View Article and Find Full Text PDF[Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS)].
Pneumologie
April 2023
Klinik für Pneumologie, Medizinische Hochschule Hannover, Hannover.
Background: The introduction of monoclonal antibodies (biologics) has revolutionized the therapy of severe asthma. Even though there is a response in the majority of patients, the degree of response varies. To date criteria for assessment of response to biologics are not consistently defined.
View Article and Find Full Text PDFSuccessful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy.
Respir Med Case Rep
November 2022
Seventh Respiratory Medicine Department and Asthma Center, Athens Chest Hospital Sotiria, Athens, Greece.
A 26-year-old female with steroid dependent eosinophilic asthma and nasal polyps who had successfully been treated with mepolizumab for 17 consecutive months with complete steroid withdrawal and symptoms control, stopped biologic treatment due to pregnancy efforts. Mepolizumab discontinuation resulted in frequent exacerbations and daily symptoms despite high dose ICS/LABA and re-initiation of oral steroids. Mepolizumab was initiated again, followed by improvement of asthma control and gradual withdrawal of steroids within 2 months.
View Article and Find Full Text PDFLong-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps.
Ann Allergy Asthma Immunol
February 2023
Sanofi, Bridgewater, New Jersey.
Background: Coexisting chronic rhinosinusitis and nasal polyps (CRS-NPs) substantially increases the disease burden of asthma. Dupilumab, a fully human monoclonal antibody, has established efficacy and an acceptable safety profile in asthma and CRS with NP.
Objective: To evaluate long-term dupilumab efficacy in TRAVERSE (NCT02134028) patients with uncontrolled, moderate-to-severe (QUEST) or oral corticosteroid (OCS)-dependent (VENTURE) asthma with or without coexisting CRS-NP.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!